BSD Medical Reports on Continued Sales Momentum by Terumo for the MicroThermX® Microwave System
March 03 2014 - 9:15AM
Business Wire
Terumo to Focus on MicroThermX Introduction in Eastern
European and Middle Eastern Markets Following Early Success in
Western Europe
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD)
(www.BSDMedical.com), a leading provider of medical systems that
treat cancer and benign diseases using heat therapy, today reported
continued sales momentum by Terumo on the distribution of the
MicroThermX® Microwave Ablation System (MicroThermX). BSD’s
exclusive, multimillion dollar agreement with Terumo Europe NV
(Terumo) covers distribution of the MicroThermX in more than 100
countries, including Europe, Western Asia and Africa, with a market
potential that exceeds $1 billion.
“Terumo has been an exceptional partner for BSD, making
substantial investments in sales and marketing of the MicroThermX,”
said Sam Maravich, Vice President of Sales and Marketing of BSD
Medical. “We are gaining sales traction in the Western European
countries. The next phases of Terumo’s plan are focused on
expanding into Eastern European markets, with the Middle East to
follow. Since the beginning of BSD's 2014 fiscal year, Terumo has
initiated marketing efforts in countries with the highest revenue
potential. Terumo continues to execute on plan and we view this
partnership as a model for future distribution collaborations with
the MicroThermX system.”
Terumo is implementing a well-planned, comprehensive marketing
strategy for the MicroThermX that is aimed at geographic expansion
and building credibility within the clinical community. Among key
aspects of the marketing strategy, Terumo is using its significant
relationships within the clinical community to establish
MicroThermX teaching centers of excellence with key opinion
leaders. Terumo is also sponsoring several studies with the
MicroThermX.
About Terumo Corporation
A world leader in state-of-the-art medical devices and
interventional oncology, Tokyo-based Terumo Corporation (TYO:
JP:4543) reported 2013 sales of nearly $5 billion and has a market
cap in excess of $8 billion. Through the sale and promotion of a
high-quality line of devices used for tumor embolization, the
closing or blocking of blood vessels, Terumo Europe NV has
established itself as a pioneer in the field of interventional
oncology.
About the MicroThermX Microwave Ablation System
The MicroThermX is a compact, mobile, state-of-the-art,
proprietary system that includes a microwave generator,
single-patient-use disposable antennas, and a thermistor-based
temperature monitoring system. The innovative design of the
MicroThermX is the first of its kind that allows delivery of higher
power levels using a single generator.
The MicroThermX utilizes innovative synchronous phased array
technology that was developed and patented by MicroThermX BSD to
provide a wide range of uniform zones of ablation. The MicroThermX
includes innovative, high-end disposables (SynchroWave antennas)
that are used in each ablation treatment and will provide a
significant ongoing revenue stream.
The soft tissue (tumor) ablation world market potential is
estimated to exceed $2.3 billion. The U.S. Food and Drug
Administration (FDA) has granted the Company a 510(k) clearance to
market the MicroThermX for ablation of soft tissue. BSD has also
received CE Marking for the MicroThermX System, which allows BSD to
market the MicroThermX in Europe. CE Marking is also recognized in
many countries outside of the EU, providing BSD the ability to
market the MicroThermX to a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and
services systems to treat cancer and benign diseases using heat
therapy delivered using focused microwave energy and radiofrequency
(RF). BSD’s product lines include ablation and hyperthermia
treatment systems. BSD’s microwave ablation system has been
developed as a stand-alone therapy to ablate and destroy soft
tissue. The Company has developed extensive intellectual property,
multiple products in the market, and well established distribution
in the United States, Europe and Asia. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors
with heat (hyperthermia), while increasing the effectiveness of
other therapies such as radiation therapy. Certain of the Company’s
products have received regulatory approvals in the United States,
Europe and China. For further information visit BSD Medical's
website at www.BSDMedical.com.
Forward-Looking Statements
Statements contained in this press release that are not
historical facts, including statements relating to our 2014 plans,
are forward-looking statements, as defined in the Private
Securities Litigation Reform Act of 1995. All forward-looking
statements are subject to risks and uncertainties detailed in the
Company's filings with the Securities and Exchange Commission,
including the market demand for our MicroThermX® products and the
regulatory requirements we face. These forward-looking statements
speak only as of the date on which such statements are made, and
the Company undertakes no obligation to update such statements to
reflect events or circumstances arising after such date, except as
required by law.
BSD Medical CorporationWilliam Barth, 801-972-5555fax:
801-972-5930investor@bsdmc.com